K2M Inc. was incorporated in 2004 and began working with leading spine surgeons for the purpose of designing, developing and commercializing innovative and proprietary complex spine technologies and techniques. In 2010, K2M Group Holdings Inc., an entity then controlled by Welsh, Carson, Andersen & Stowe, acquired K2M Inc. Certain affiliates of Welsh, Carson, Anderson & Stowe are referred to herein as “WCAS,” and WCAS, and together with the other owners of K2M Group Holdings Inc. prior to our May 2014 initial public offering, are collectively referred to as our “pre-IPO owners.” Since 2010, we have continued to invest in our business by expanding our global distribution network including through the investment of additional capital raised from our pre-IPO owners, our initial public offering in May 2014, subsequent public offerings in February and July 2015 and issuance of convertible senior notes in August 2016. As of March 2017, WCAS is no longer a shareholder of K2M Group Holdings Inc. Until the end of 2017, we were an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended, as modified by the JOBS Act of 2012. Based on the aggregate market value of our common stock held by non-affiliates as of June 30, 2017, we no longer qualify as an “emerging growth company” and are no longer exempt from various reporting requirements applicable to other public companies. We are a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Our complex spine products are used by spine surgeons to treat some of the most difficult and challenging spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. We believe these procedures typically receive a higher rate of positive insurance coverage and often generate more revenue per procedure as compared to traditional degenerative spine surgery procedures. We have applied our product development expertise in innovating complex spine technologies and techniques to the design, development and commercialization of an expanding number of proprietary minimally invasive surgery (“MIS”) products. These proprietary MIS products are designed to allow for less invasive access to the spine and faster patient recovery times as compared to traditional open access surgical approaches. In addition, we have utilized these core competencies in the design, development and commercialization of a comprehensive portfolio of products designed for use with patients suffering from degenerative spinal conditions.
Company profile
Website
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
19 Nov 18
EFFECT
Notice of effectiveness
19 Nov 18
8-K
Entry into a Material Definitive Agreement
15 Nov 18
POS AM
Prospectus update (post-effective amendment)
9 Nov 18
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 18
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 18
25-NSE
Exchange delisting
9 Nov 18
8-K
Termination of a Material Definitive Agreement
9 Nov 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
8-K
Other Events
7 Nov 18
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|